0 688

Cited 136 times in

Therapeutic implications of cancer epithelial-mesenchymal transition (EMT)

DC Field Value Language
dc.contributor.author김남희-
dc.contributor.author육종인-
dc.contributor.author조은애산드라-
dc.date.accessioned2019-07-23T06:56:48Z-
dc.date.available2019-07-23T06:56:48Z-
dc.date.issued2019-
dc.identifier.issn0253-6269-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/170389-
dc.description.abstractTheepithelial-mesenchymal transition(EMT) comprises an essential biological process involvingcancerprogression as well as initiation. While theEMThas been regarded as a phenotypic conversion fromepithelialtomesenchymalcells, recent evidence indicates that it plays a critical role in stemness, metabolic reprogramming, immune evasion andtherapeuticresistance ofcancercells. Interestingly, several transcriptional repressors including Snail (SNAI1), Slug (SNAI2) and the ZEB family constitute key players forEMTincanceras well as in the developmental process. Note that the dynamic conversion betweenEMTandepithelialreversion (mesenchymal-epithelialtransition, MET) occurs through variable intermediate-hybrid states rather than being a binary process. Given the close connection between oncogenic signaling andEMTrepressors, theEMThas emerged as atherapeutictarget or goal (in terms of MET reversion) incancertherapy. Here we review the critical role ofEMTintherapeuticresistance and the importance ofEMTas atherapeutictarget for humancancer.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherPharmaceutical Society of Korea-
dc.relation.isPartOfARCHIVES OF PHARMACAL RESEARCH-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAnimals-
dc.subject.MESHAntineoplastic Agents/administration & dosage-
dc.subject.MESHAntineoplastic Agents/metabolism-
dc.subject.MESHCell Line,Tumor-
dc.subject.MESHEpithelial-Mesenchymal Transition/drug effects-
dc.subject.MESHHumans-
dc.subject.MESHNeoplasms/drug therapy-
dc.subject.MESHNeoplasms/metabolism-
dc.subject.MESHNeoplasms/pathology-
dc.subject.MESHSignal Transduction/drug effects-
dc.subject.MESHSignal Transduction/physiology-
dc.subject.MESHTranscription Factors/antagonists & inhibitors-
dc.subject.MESHTranscription Factors/metabolism-
dc.titleTherapeutic implications of cancer epithelial-mesenchymal transition (EMT)-
dc.typeArticle-
dc.contributor.collegeResearch Institutes (연구소)-
dc.contributor.departmentOral Cancer Research Institute (구강종양연구소)-
dc.contributor.googleauthorEunae Sandra Cho-
dc.contributor.googleauthorHee Eun Kang-
dc.contributor.googleauthorNam Hee Kim-
dc.contributor.googleauthorJong In Yook-
dc.identifier.doi10.1007/s12272-018-01108-7-
dc.contributor.localIdA00360-
dc.contributor.localIdA02536-
dc.contributor.localIdA04799-
dc.relation.journalcodeJ00229-
dc.identifier.pmid30649699-
dc.identifier.urlhttps://link.springer.com/article/10.1007%2Fs12272-018-01108-7-
dc.subject.keywordEMT-
dc.subject.keywordEpithelial-mesenchymal transition-
dc.subject.keywordOncogenes-
dc.subject.keywordSnail-
dc.subject.keywordTherapeuticresistance-
dc.subject.keywordWnt-
dc.contributor.alternativeNameKim, Nam Hee-
dc.contributor.affiliatedAuthor김남희-
dc.contributor.affiliatedAuthor육종인-
dc.contributor.affiliatedAuthor조은애산드라-
dc.citation.volume42-
dc.citation.number1-
dc.citation.startPage14-
dc.citation.endPage24-
dc.identifier.bibliographicCitationARCHIVES OF PHARMACAL RESEARCH, Vol.42(1) : 14-24, 2019-
dc.identifier.rimsid62850-
dc.type.rimsART-
Appears in Collections:
2. College of Dentistry (치과대학) > Research Institute (부설연구소) > 1. Journal Papers
2. College of Dentistry (치과대학) > Dept. of Oral Pathology (구강병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.